Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment

Leukemia and Lymphoma

Volumn 34, Issue 1-2, 1999, Pages 35-43

  Dhodapkar, Madhav V ^a   Sanderson, Ralph D ^b,c  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Heparan sulfate; HIV; Hodgkin's disease; Lymphoma; Myeloma; Proteoglycan; Syndecan

Indexed keywords

COLLAGEN TYPE 1; PROTEOGLYCAN; SYNDECAN;

APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL SURFACE; CELL SURVIVAL; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; MYELOMA; MYELOMA CELL; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

EID: 0033025034     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909083378     Document Type: Review

References (53)

1. Carey, D. J. (1997) Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327:1-16.
2. Bernfield, M., R. Kokenyesi, M. Kato, M. T. Hinkes, J. Spring, R. L. Gallo, and E. J. Lose. (1992) Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8:365-393.
3. Sanderson, R. D., P. Lalor, and M. Bernfield. (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1 :27-35.
4. Ridley, R. C., H. Xiao, H. Hata, J. Woodliff, J. Epstein, and R. D. Sanderson. (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767-774.
5. Gaidano, G., A. Gloghini, V. Gattei, M. F. Rossi, A. M. Cilia, C. Godeas, M. Degan, T. Perin, V. Canzonieri, D. Aldinucci, G. Saglio, A. Carbone, and A. Pinto. (1997) Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 90:4894-900.
6. Carbone, A., A. Gloghini, V. Gattei, M. Degan, S. Improta, D. Aldinucci, V. Canzonieri, T. Perin, R. Volpe, G. Gaidano, V. Zagonel, and A. Pinto. (1997) Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cellspecific monoclonal antibody B-B4 and express human syndecan-1. Blood89:3787-3794.
7. Carbone, A., G. Gaidano, A. Gloghini, L. M. Larocca, D. Capello, V. Canzonieri, A. Antinori, U. Tirelli, B. Falini, and R. Dalla-Favera. (1998) Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 91 :747-755.
8. Wijdenes, J., W. C. Vooijs, C. Clement, J. Post, F. Morard, N. Vita, P. Laurent, R. X. Sun, B. Klein, and J. M. Dore. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 94:318-323.
9. +malignant plasma cells. J. Immunol. Methods 205:73-79.
10. Jourdan, M., M. Ferlin, E. Legouffe, M. Horvathova, J. Liautard, J. F. Rossi, J. Wijdenes, J. Brochier, and B. Klein. (1998) The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br. J. Haematol. 100:637-646.
11. Schneider, U., A. van Lessen, D. Huhn, and S. Serke. (1997) Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br. J. Haematol. 97:56-64.
12. Rawstron, A. C., R. G. Owen, F. E. Davies, R. J. Johnson, R. A. Jones, S. J. Richards, P. A. Evans, J. A. Child, G. M. Smith, A. S. Jack, and G. J. Morgan. (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97:46-55.
13. Dhodapkar, M. V., E. Abe, A. Theus, M. Lacy, J. K. Langford, B. Barlogie, and R. D. Sanderson. (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91:2679-2688.
14. Dhodapkar, M. V., T. Kelly, A. Theus, A. B. Athota, B. Barlogie, and R. D. Sanderson. (1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol 99:368-371.
15. Khoory, M. S., M. E. Nesheim, E. J. Bowie, and K. G. Mann. (1980) Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J. Clin. Invest. 65:666-674.
16. Palmer, R. N., M. E. Rick, P. D. Rick, J. A. Zeller, and H. R. Gralnick. (1984) Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N. Engl. J. Med. 310:1696-1699.
17. Chapman, G. S., C. B. George, and D. L. Danley. (1985) Heparin-like anticoagulant associated with plasma cell myeloma. Am. J. Clin. Pathol. 83:764766.
18. Kaufman, P. A., J. P. Gockerman, and C. S. Greenberg. (1989) Production of a novel anticoagulant by neoplastic plasma cells: Report of a case and review of the literature. Am. J. Med. 86:612-616.
19. Subramanian, S. V., M. L. Fitzgerald, and M. Bernfield. (1997) Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272:14713-14720.
20. Kainulainen, V., H. Wang, C. Schick, and M. Bernfield. (1998) Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 273:11563-11569.
21. Fitzgerald, M. L., and M. Bernfield. (1997) Shedding of syndecan ectodomains is regulated by multiple pathways and metalloproteinase-dependent. Mol. Biol. Cell.8:393a.
22. Teoh, G., and K. C. Anderson. (1997) Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am. 11 :27-42.
23. Sanderson, R. D., T. B. Sneed, L. A. Young, G. L. Sullivan, and A. D. Lander. (1992) Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan. J. Immunol. 148 :3902-3911.
24. Sanderson, R. D., J. E. Turnbull, J. T. Gallagher, and A. D. Lander. (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J. Biol. Chem. 269:13100-13106.
25. Stanley, M. J., B. F. Liebersbach, W. Liu, D. J. Anhalt, and R. D. Sanderson. (1995) Heparan sulfate-mediated cell aggregation. Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells. J. Biol. Chem. 270:5077-5083.
26. Liebersbach, B. F., and R. D. Sanderson. (1994) Expression of syndecan-1 inhibits cell invasion into type 1 collagen. J. Biol. Chem. 269:20013-20019.
27. Mali, M., H. Andtfolk, H. M. Miettinen, and M. Jalkanen. (1994) Suppression of tumor cell growth by syndecan-1 ectodomain. J. Biol. Chem. 269:27795-27798.
28. Numa, F., K. Hirabayashi, N. Tsunaga, H. Kato, K. O'Rourke, H. Shao, C. Stechmann-Lebakken, J. Varani, A. Rapraeger, and V. M. Dixit. (1995) Elevated levels of syndecan-1 expression confer potent serum-dependent growth in human 293t cells. Cancer Res. 55 :4676-4680.
29. Santra, M., T. Skorski, B. Calabretta, E. C. Lattime, and R. V. lozzo. (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. USA. 92:7016-7020.
30. Deluca, A., M. Santra, A. Baldi, A. Giordano, and R. V. lozzo. (1996) Decorin induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 271:18961-18965.
31. Mathiak, M., C. Yenisey, D. S. Grant, B. Sharma, and R. V. lozzo. (1997) A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res. 57:2130-2136.
32. Smith, K. G. C., T. D. Hewitson, G. J. V. Nossal, and D. M. Tarlinton. (1996) The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 26:444-448.
33. Borset, M., E. Lien, T. Espevik, E. Helseth, A. Waage, and A. Sundan. (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-met in human myeloma cell lines. J. Biol. Chem. 271:24655-24661.
34. Borset, M., H. Hjorthhansen, C. Seidel, A. Sundan, and A. Waage. (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood88:3998-4004.
35. Seidel, C., M. Borset, I. Turesson, N. Abildgaard, A. Sundan, and A. Waage. (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91:806-812.
36. Kato, M., H. Wang, V. Kainulainen, M. L. Fitzgerald, S. Ledbetter, D. M. Omitz, and M. Bernfield. (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4:691-697.
37. Bataille, R., S. C. Manolagas, and J. R. Berenson. (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol. Oncol Clin. North Am. 11:349-361.
38. Bataille, R., D. Chappard, C. Marcelli, P. Dessauw, P. Baldet, J. Sany, and C. Alexandre. (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest.88:62-66.
39. Bataille, R., D. Chappard, C. Marcelli, P. Dessauw, J. Sany, P. Baldet, and C. Alexandre. (1989) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol.7:1909-1914.
40. Mundy, G. R., L. G. Raisz, R. A. Cooper, G. P. Schechter, and S. E. Salmon. (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 291:1041-1046.
41. Kawano, M., I. Yamamoto, K. Iwato, H. Tanaka, H. Asaoku, O. Tanabe, H. Ishikawa, M. Nobuyoshi, Y. Ohmoto, Y. Hirai, and et al. (1989) Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646-1649.
42. Carter, A., S. Merchav, I. Silvian-Draxler, and I. Tatarsky. (1990) The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. 74:424-431.
43. Delaisse, J. M., Y. Eeckhout, and G. Vaes. (1988) Bone-resorbing agents affect the production and distribution of procollagenase as well as the activity of collagenase in bone tissue. Endocrinology 123:264-276.
44. Fuller, K., T. J. Chambers, and A. C. Gallagher. (1991) Heparin augments osteoclast resorption-stimulating activity in serum. J. Cell. Physiol. 147:208-214.
45. Chowdhury, M. H., C. Hamada, and D. W. Dempster. (1992) Effects of heparin on osteoclast activity. J. Bone Miner. Res. 7:771-777.
46. Shaughnessy, S. G., E. Young, P. Deschamps, and J. Hirsh. (1995) The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368-1373.
47. Chen, Y., M. Bei, I. Woo, I. Satokata, and R. Maas. (1996) Msx1 controls inductive signaling in mammalian tooth morphogenesis. Development 122 :3035-3044.
48. Gallo, R., C. Kim, R. Kokenyesi, N. S. Adzick, and M. Bernfield. (1996) Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J. Invest. Dematol. 107:676-683.
49. Rettig, M. B., H. J. Ma, R. A. Vescio, M. Pold, G. Schiller, D. Belson, A. Savage, C. Nishikubo, C. Wu, J. Fraser, J. W. Said, and J. R. Berenson. (1997) Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-1854.
50. Said, J. W., M. R. Rettig, K. Heppner, R. A. Vescio, G. Schiller, H. J. Ma, D. Belson, A. Savage, I. P. Shintaku, H. P. Koeffler, H. Asou, G. Pinkus, J. Pinkus, M. Schrage, E. Green, and J. R. Berenson. (1997) Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 90:4278-4282.
51. Shieh, M. T., and P.G. Spear. (1994) Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin. J. Virol. 68 :1224-1228.
52. Immergluck, L. C., M. S. Domowicz, N. B. Schwartz, and B. C. Herold. (1998) Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells. J. Gen. Virol. 79:549-559.
53. Liu, W., E.D. Litwack, M.J. Stanley, J.K. Langford, A.D. Lander, and R.D. Sanderson. (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypicans have distinct functions. J. Biol. Chem. 273: 22, 825-22832.